Replies to post #145 on Adaptimmune Therapeutics PLC (ADAP)

[jondoeuk]

Armed with these encouraging preliminary data, and with more data on the way, Adaptimmune is gearing up for its first regulatory filing for afami-cel as a treatment for advanced synovial sarcoma in 2022.

SPEARHEAD-1 full data will be at CTOS.

Meanwhile, the biotech also has plans to expand into several additional solid tumor types, such as liver, lung, and head and neck cancers.

A second registration-directed PhII (in esophageal or esophagogastric junction) will open soon and trials are already ongoing in HCC (data at ILCA), lung and H&N (data at ESMO)